Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly.
about
Hepatitis B virus therapy: What's the future holding for us?Single-particle electrophoresis in nanochannels.High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core proteinPresent and future therapies of hepatitis B: From discovery to cureTreatment options beyond IFNα and NUCs for chronic HBV infection: expectations for tomorrow.Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview.Chronic hepatitis B: A wave of new therapies on the horizon.Core protein: A pleiotropic keystone in the HBV lifecycle.Future therapy for hepatitis B virus infection.New paradigms in hepatitis B management: only diamonds are forever.Hepatitis B: treatment choice and monitoring for response and resistance.Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA VariantsThe current status and future directions of hepatitis B antiviral drug discovery.Eradication Strategies for Chronic Hepatitis B Infection.Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined ModalitiesFrom HCV To HBV Cure.New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection.Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular MechanismsDesign, Synthesis, and Evaluation of Tetrahydropyrrolo[1,2-c]pyrimidines as Capsid Assembly Inhibitors for HBV Treatment.HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways.Hepatitis B core protein as a therapeutic target.Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles.The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells.Drugs in Development for Hepatitis B.Molecular jenga: the percolation phase transition (collapse) in virus capsids
P2860
Q26774198-A7690E50-A003-498E-A047-21F6C1E9FF98Q30397780-0111DEB2-2BF7-4E17-8F56-D2058478B8BDQ36371517-3CA22D1C-8BEB-40A2-8EE8-32B0668F4FD7Q36378278-4026738A-012B-4CB7-998D-DFEC527B0162Q38255840-8E6D82EA-B020-4557-8183-279543591336Q38447283-4BDB104C-E4CA-4F6D-8A6A-1873C576A88CQ38538107-81796CB5-C3E9-4C4B-8934-C17E28B1D0CAQ38541052-7E74024F-19D6-49AE-92D0-5CC1CF103A8AQ38565056-CC4796A6-C213-45A6-B145-C4C8A5E6F77FQ38588187-64254532-8AAC-48F8-8D39-E69146FE199BQ38707903-3B4AF68A-2433-4D1E-80E3-55BB58772719Q38720992-298423F5-DD27-437F-8F4A-7E284ADE0123Q38755680-0AC494D2-9745-44D5-821F-6E64CA360AEFQ38802098-EDD661E9-8BA9-4C84-80A8-2703B5250329Q38837065-0CA302A5-DA3D-4B1B-AFC2-EF3BB74F50C2Q38980907-E1CF7A2A-BE3F-447A-8EBD-80EDCA92FCE0Q39067338-26D25FB0-FE05-4EE8-8838-B476558F4630Q40130098-17664FFA-3B82-4966-BE7B-8B4DC5D21618Q40178518-49E2F41F-67E0-4EBB-8BA6-E2A264746F72Q40330419-4E74DAE8-3683-440F-8678-4608D4D2C168Q41930281-A4064C79-DB73-4977-8BB6-2A062E201916Q41930702-26C9E556-ACCB-4FF3-A244-42175E0388FBQ47601905-015F8E43-5C87-4E3D-9785-1D7F6487C0CCQ50043349-B0D5592A-BC6B-48AE-B7AF-9AFB2BE47B05Q52579709-AED6BA74-F340-482B-B44A-92339CA128A8Q52764230-2278B799-F2FC-4351-96C0-847B7F484AF5Q57445701-2C5A50F8-DAE0-424B-9BCA-6A8EB9AACA91
P2860
Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preclinical characterization o ...... virus core particle assembly.
@en
Preclinical characterization o ...... virus core particle assembly.
@nl
type
label
Preclinical characterization o ...... virus core particle assembly.
@en
Preclinical characterization o ...... virus core particle assembly.
@nl
prefLabel
Preclinical characterization o ...... virus core particle assembly.
@en
Preclinical characterization o ...... virus core particle assembly.
@nl
P2093
P2860
P356
P1476
Preclinical characterization o ...... virus core particle assembly.
@en
P2093
Alla Arzumanyan
Faxhou Zhang
Marcia M Clayton
Mark A Feitelson
Qingyun Ren
Siegfried Goldmann
Yingjun Zhang
P2860
P304
P356
10.1128/AAC.01091-13
P407
P577
2013-08-19T00:00:00Z